Medicenna Therapeutics logo

Medicenna Therapeutics(OTC) MDNA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-80%
5 Year-87%
1 Year-55%
1 Month+2%
N/A
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.312026-10-13
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.42%USD 0.312026-10-06
1 month+1.8%USD 0.302026-09-11
3 month+19.37%USD 0.262026-07-15
Year to date-54.81%USD 0.682025-12-31
1 year-54.62%USD 0.672025-10-13
3 year+3.95%USD 0.292023-10-13
5 year-87.42%USD 2.432021-10-14
Since inception-79.57%USD 1.502017-09-20

Medicenna Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$14.07M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Jun 25, 2024

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing innovative treatments for cancer, inflammation, and immune-mediated diseases. The company specializes in Superkines and empowered Superkines, with a robust pipeline aimed at addressing significant unmet medical needs.

Products and Services
  • Bizaxofusp targets interleukin-4 for recurrent glioblastoma treatment
  • MDNA11 activates anti-cancer immune cells via interleukin-2
  • MDNA113 is a bifunctional anti-PD-1-IL-2 superkine for cancer therapy
Growth Outlook
  • Strong pipeline with multiple candidates in clinical and preclinical stages
  • Potential market expansion as immunotherapy gains traction in oncology
  • Strategic partnerships may enhance development and commercialization efforts
Financial Highlights
  • Recent quarterly net income of -$2.35 million reflects ongoing R&D investments
  • Cash at the end of the period was $5.39 million, supporting operational needs
  • Operating expenses totaled $2.55 million, indicating a focus on growth
Medicenna Therapeutics Corp. is positioned in the biotechnology sector, with a focus on innovative immunotherapy solutions. The company’s pipeline includes several promising candidates that target critical pathways in cancer treatment. The recent financial data indicates a commitment to research and development, which is essential for long-term growth. With a solid cash position, Medicenna is well-equipped to continue its development efforts and potentially capitalize on the growing demand for effective cancer therapies. The strategic focus on Superkines may provide a competitive edge in the evolving landscape of immunotherapy.
AI Generated • Sep 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-55.29%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$22.58M

EBITDA

-CA$19.14M

Operating Cash Flow

-CA$13.34M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$13.34M

Cash & ST Invst.

CA$25.69M

Total Debt

CA$0.00

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-12-31N/A
Q42023-03-31N/A
Q12023-06-30N/A
Q22023-09-30N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.12-64.6%
20242024-03-31CAD -0.27131.1%
20252025-03-31CAD -0.11-59.2%
20262026-03-31CAD -0.1644.6%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-12-31-28.3%
Q42023-03-31-305.6%
Q12023-06-3052.4%
Q22023-09-30-30.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-CA$3.72M

-251.9%

EBITDA

-CA$6.81M

-43.9%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

CA$25.69M

-35.8%

Total Debt

CA$0.00

N/A

Accounts Receivable

CA$306.00K

+105.4%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-CA$3.92M

+10.9%

Operating Cash Flow

-CA$3.92M

+10.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCCCyclacel Pharmaceuticals, Inc.
$6.37-5.98%
AMTIApplied Molecular Transport Inc.
$0.26-3.13%
KRROKorro Bio, Inc.
$8.67-1.65%
HURATuHURA Biosciences, Inc.
$1.73-4.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.99+1.06%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at N/A per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between N/A and N/A.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$73.30K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$4.01M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services